Back
Compare AU
Compare QLTY vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Global Quality Leaders ETF (QLTY) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
QLTY | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 142 | 76 |
Median incremental investment | $1,131.90 | $674.27 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,595.20 | $2,388.76 |
Average age group | > 35 | > 35 |
Key Summary
QLTY | CURE | |
|---|---|---|
Strategy | QLTY.AX was created on 2018-11-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. QLTY.AX aims to track an index (before fees and expenses) that comprises 150 global companies (ex-Australia) ranked by highest quality score | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | NZD - NEW ZEALAND DOLLAR (0 %) PALANTIR TECHNOLOGIES INC (2.54 %) MICROSOFT CORP (2.36 %) | Moderna Inc (2.65 %) Twist Bioscience Corp (1.84 %) Oruka Therapeutics Inc (1.50 %) |
Top 3 industries | Other (32.16 %) Information Technology (27.22 %) Industrials (11.08 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (70.25 %) Japan (11.37 %) Switzerland (4.35 %) | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) |
Management fee | 0.35 % | 0.45 % |
Key Summary
QLTY | CURE | |
|---|---|---|
Issuer | BetaShares | Global X |
Tracking index | iSTOXX MUTB Global ex-Australia Quality Leaders Index - AUD | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.35 % | 0.45 % |
Price | $33.48 | $78.32 |
Size | $1.018 billion | $51.667 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 2.34 % | 0.03 % |
Market | ASX | ASX |
First listed date | 07/11/2018 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
QLTY | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 142 | 76 |
Median incremental investment | $1,131.90 | $674.27 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,595.20 | $2,388.76 |
Average age group | > 35 | > 35 |
Pros and Cons
QLTY | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
QLTY | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |